Novo delivered quarterly earnings that exceeded analyst expectations early Wednesday, driven by strong commercial demand for its Wegovy pill that beat estimates. The Danish weight-loss manufacturer used the positive performance to increase its financial projections for the full year. This turnaround arrives as the business attempts to recover after a tumultuous year marked by losing ground to primary rival Eli Lilly.
Novo posted quarterly earnings ahead of expectations early Wednesday as sales of its Wegovy pill blew past estimates.
The Danish weight-loss drug maker is looking to regain momentum following a tumultuous year in which it fell behind rival Eli Lilly.
This is a breaking news story. Please refresh for updates.
Jeweller Pandora has slightly raised its financial outlook for 2026. The upgraded forecast is supported by strong consumer demand for the company's novelty items.
The German automotive manufacturer faces mounting pressure as internal transformation initiatives continue to erode profitability during the current fiscal cycle. Executives anticipate that these organizational shifts will extend operational and balance sheet strains into the final months of the year.
Investors responded aggressively to operational milestones and profit expansion across the company's enterprise-focused workspace portfolio. The provider saw net profit nearly double alongside solid top-line growth driven by consistent demand from Global Capability Centres and large corporate clients. This sharp operational rebound offers immediate momentum to a stock that has struggled significantly over the broader annual horizon.